Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Minich SS.

Ann Pharmacother. 2012 Mar;46(3):377-83. doi: 10.1345/aph.1Q680. Epub 2012 Mar 6. Review.

PMID:
22395252
2.

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F.

Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.

3.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, Yokoyama M, Takubo T, Kagehara H, Matsushima T.

Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.

4.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D.

Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Review.

PMID:
23515511
5.

Brentuximab vedotin in anaplastic large cell lymphoma.

Skarbnik AP, Smith MR.

Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27.

PMID:
22449148
6.

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A.

J Hematol Oncol. 2014 Mar 19;7:24. doi: 10.1186/1756-8722-7-24.

7.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A.

N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.

8.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
9.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
10.
11.

Brentuximab vedotin in systemic T-cell lymphoma.

Oki Y, Younes A.

Expert Opin Biol Ther. 2012 May;12(5):623-32. doi: 10.1517/14712598.2012.670216. Epub 2012 Mar 20.

PMID:
22428917
12.

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.

Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V.

Crit Rev Oncol Hematol. 2015 Sep;95(3):359-69. doi: 10.1016/j.critrevonc.2015.03.011. Epub 2015 Apr 27. Review.

PMID:
25964164
13.

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Chen X, Soma LA, Fromm JR.

Onco Targets Ther. 2013 Dec 19;7:45-56. doi: 10.2147/OTT.S39107. Review.

14.

Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.

Haddley K.

Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435. Review.

PMID:
22536568
15.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.

J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.

PMID:
22614995
16.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A.

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

17.

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.

Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Review. French.

PMID:
23831822
18.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A.

Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.

19.

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.

Ansell SM.

Expert Opin Investig Drugs. 2011 Jan;20(1):99-105. doi: 10.1517/13543784.2011.542147. Epub 2010 Dec 2. Review.

PMID:
21121873
20.

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Vaklavas C, Forero-Torres A.

Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.

Supplemental Content

Support Center